Incyte
Company type | Public |
---|---|
Nasdaq: INCY NASDAQ-100 Component S&P 500 Component | |
Industry | pharmaceutical company |
Founded | 1991 |
Headquarters | , United States |
Key people | Hervé Hoppenot (President and CEO, 2014) |
Revenue | $US 1.5 billion (2017) |
$US (313) million (2017) | |
Total assets | $US 1.504 billion (2017) |
Total equity | $US 1.632 billion (2017) |
Number of employees | ~700[1] |
Website | www.incyte.com |
Footnotes / references [2] |
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.[3] The company was founded in Palo Alto, California in 1991 and went public in 1993.[1]
Incyte has one drug, Jakafi, which has been approved by the U.S. Food and Drug Administration (FDA) and has been prescribed to patients in the United States.[3]
As of 2014, the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly.[4][5] It gained EU approval in February 2017.[6] In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety.[7][8]
As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck's pembrolizumab (Keytruda) and Bristol Myers Squibb's nivolumab (Opdivo).[9][10]
In 2013, Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060).[11]
History
In 2014, Incyte named Hervé Hoppenot president and CEO.[12] Hoppenot had previously served as the president of Novartis Oncology; he had been with Novartis since 2003.[12]
In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal worth $795+ million.[13]
In January 2020, Incyte signed a collaboration and license agreement for the global development and commercialization of tafasitamab with MorphoSys.[14] On March 3, 2020, the agreement received antitrust clearance and thus became effective.[15]
References
- ^ a b Scott Goss (2 Mar 2015). "Incyte is Delaware Bio Company of the Year, again". delawareonline.com. Retrieved 2 Mar 2015.
- ^ Incyte Corporation (2012), Form 10-K (SEC filing), Incyte Corporation (published February 22, 2012), Commission File Number: 0-27488, archived from the original on January 26, 2013, retrieved May 6, 2012
- ^ a b Natoli, Cori Anne (May 5, 2012), "Incyte looks to ride on drug's success", The News Journal, retrieved May 6, 2012
- ^ "Lilly, Incyte Treatment Shows Positive Results". www.insideindianabusiness.com. 9 Dec 2014. Archived from the original on 8 March 2015. Retrieved 2 Mar 2015.
- ^ "Baricitinib" (pdf). Statement on a nonproprietary name adopted by the USAN council. American Medical Association.
- ^ Ramsey, L (17 April 2017). "The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling". Business Insider.
- ^ Grant, Ch (14 April 2017). "Surprise FDA Rejection Will Sting This Biotech". The Wall Street Journal.
- ^ Brochez, L; Chevolet, I; Kruse, V (May 2017). "The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy". European journal of cancer (Oxford, England : 1990). 76: 167–182. doi:10.1016/j.ejca.2017.01.011. PMID 28324751.
- ^ Tracy Staton (Apr 3, 2017). "Racing in lung cancer again (or still), Merck and BMS expand Incyte combo trials". FiercePharma.
- ^ "Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development | Business Wire". www.businesswire.com. Retrieved 2015-12-29.
- ^ a b "People". Gen. Eng. Biotechnol. News (paper). Vol. 34, no. 4. February 15, 2014. p. 41.
- ^ "Incyte to Co-Develop Hengrui's SHR-1210 in Up-to-$795M+ Deal". Genetic Engineering & Biotechnology News. 2 September 2015.
- ^ "MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab".
- ^ "MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab".
External links
- Business data for Incyte:
- Companies in the Nasdaq-100
- Companies listed on the Nasdaq
- American companies established in 1991
- Companies based in New Castle County, Delaware
- Pharmaceutical companies established in 1991
- Companies listed on NASDAQ
- 1991 establishments in California
- Pharmaceutical companies of the United States
- Life sciences industry
- Health care companies based in Delaware
- 1993 initial public offerings